|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 1 | Inactivated Retroviruses That Retain Functional and Structural Envelope Proteins: Use as Vaccines and in Vitro Reagents
L. O. Arthur*1, R. Benveniste2, R. Desrosiers3, J. Hoxie4, E. N. Chertova1, J. W. Bess1, L. E. Henderson1, and J. D. Lifson1 1AVP, SAIC Frederick, NCI-FCRDC, Frederick, MD, USA; 2NCI, LGD, Frederick, MD, USA; 3Harvard Med. Sch., NERPRC, Southborough, MA, USA; 4Univ. of Pennsylvania, Philadelphia, USA |
| 2 | SIV Vaccines Based on Adeno-Associated Virus Vectors
P. Johnson*1, B. Schnepp1, D. Montefiori2, N. Letvin3, and R. Clark1 1Columbus Children's Res. Inst., OH, USA; 2Duke Univ., Durham, NC, USA; and 3Beth Israel Deaconess Med. Ctr., Boston, MA, USA |
| 3 | Protective Immunity Induced by Whole Recombinant Yeast-Based HIV Vaccine
R. C. Duke1,2, A. S. Stubbs2, J. Sun2, D. Chan2, T. Whisenand1, K. Hance1, D. Bellgrau1,2, C. C. Wilson2, and A. Franzusoff*1 1GlobeImmune, Inc., Denver, CO, USA and 2Univ. of Colorado Hlth. Sci. Ctr., Denver, USA |
| 4 | Modifications of HIV Envelope Enhance Immunogenicity for Genetic Immunization
B. Chakrabarti*1, W. Kong1, B. Wu2, Z. Y. Yang1, J. Friborg3, X. Ling1, S. R. King4, and G. J. Nabel1 1Vaccine Res. Ctr., NIAID, NIH, Bethesda, MD, USA; 2Handylab, Ann Arbor, MI, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA; and 4Univ. of Michigan, Ann Arbor, USA |
| 5 | Genetic Analysis of Cell Targeting and Immunogenicity of VEE Vectors
A. West*1, E. Richmond1, E. Reap2, S. Dryga2, M. Collier1, G. MacDonald1, M. Connell3, P. Johnson3, N. Davis1, and R. Johnston1 1Univ. of North Carolina, Chapel Hill, USA; 2AlphaVax, Inc., Res. Triangle Park, NC, USA; 3 Children's Res. Inst., Columbus, OH, USA |
| 6 | Generating Novel HIV-1 Envelope Vaccine Candidates Using DNA Shuffling Technology
L. Xu1, W. Zhang1, X. Du1, D. R. Burton2, P. W. H. I. Parren2, and R. G. Whalen*1 1Maxygen, Inc., Redwood City, CA, USA and 2The Scripps Res. Inst., La Jolla, CA, USA |
| 7 | Potent CD4+ T-Cell Responses Elicited by a Dicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF
S. Santra*1, D. H. Barouch1, K. Tenner-Racz2, P. Racz2, M. J. Kuroda1, J. E. Schmitz1, S. S. Jackson1, M. A. Lifton1, D. C. Freed3, H. C. Perry3, M.-E. Davies3, J. W. Shiver3, and N. L. Letvin1. 1Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA, USA; 2Bernhard-Nocht-Inst. for Tropical Med., Hamburg, Germany; and 3Merck Res. Labs, West Point, PA, USA |
| 8 | The Use of Flt3 Ligand as an Adjuvant for Hepatitis B Vaccination of Healthy Adults
T. G. Evans*1, M. Hasan2, L. Galibert3, and D. Caron3 1Univ. of California, Davis, USA; 2Univ. of Rochester, NY, USA; and 3Immunex Corp., Seattle, WA, USA |
| 9 | Development of a Synthetic Scrambled Antigen Vaccine (SAVINE) Designed for Global Use That Includes All HIV-1 Proteins
S. A. Thomson*1, M. Shoobridge1, A. B. Jaramillo2, S. Kent3, R. A. Ffrench2 and I. A. Ramshaw1 1JCSMR, Australian Natl. Univ., ACT, Australia; 2Westfield Res. Labs., Sydney Children’s Hosp., NSW, Australia; and 3Dept. Micro. Immunol., Univ. of Melbourne, VIC, Australia |
| 10 | Plasmid Delivery Technologies Enhance Anti-HIV Immune Responses in Rhesus Macaques Given a DNA Prime-Protein Boost Vaccination Regimen
G. Otten*1, M. Schaefer1, B. Doe1, I. Srivastava1, J. Kazzaz1, Y. Lian1, H. Liu1, L. Leung1, M. Singh1, Y. Sun1, M. Ugozzoli1, J. zur Megede1, M. Lewis2, N. Miller3, G. Widera4, S. Barnett1, J. Donnelly1, D. O'Hagan1, J. Polo1, and J. Ulmer1 1Chiron Corp., Emeryville, CA, USA; 2Southern Res. Inst., Frederick, MD, USA; 3NIH, Bethesda, MD, USA; and 4Genetronics, San Diego, CA, USA |
| 11 | Immunization of Baboons (Papio cynocephalus hamadryas) Using a DNA Vaccine Formulated with Cationic Liposomes and Genetic Adjuvants
C. P. Locher*1, S. A. Witt1, B. M. Ashlock1, G. L. Kropp1, R. M. Grant1, A. M. Schmidt2, M. Agy2, D. M. Anderson2, C. J. Wheeler3, and J. A. Levy1 1Univ. of California, San Francisco, USA; 2Univ. of Washington, Seattle, USA; and 3Vical Corp., San Diego, CA, USA |
| 12 | A Novel Virus-Receptor Immunization Strategy toward SIV or HIV
T. Lehner*1, W. M. J. M. Bogers2, H. Oostermeijer2, J. L. Heeney2, J. Ma1, L. A. Bergmeier1, M. Singh3, Y. Wang1, K. Babaahmady1, G. Balarajah1, and C. G. Kelly1 1Guy’s, King’s & St Thomas’ Hosp. Med. Sch., London, UK; 2Biomedical Res. Ctr., Rijswijk, The Netherlands; and 3Lionex Diagnostics & Therapeutics, Braunschweig, Germany |